AustraliaHealth

HITIQ (ASX:HIQ) executed a non-dilutive grant agreement with the Victorian Government to heavily bolster its domestic operations.

Imugene (ASX:IMU) has released Phase 1b data for its innovative allogeneic CD19 CAR T-cell therapy, azer-cel.

PainChek (ASX:PCK) entered into binding agreements to raise $5.5 million through the issuance of unsecured convertible notes.

Bio-Gene Technology (ASX:BGT) announced an expansion of its vector control programmes into Asia.

Avecho Biotechnology (ASX:AVE) completed the treatment phase for its Phase 3 insomnia trial, keeping interim analysis results on track for late June.

OncoSil Medical (ASX:OSL) shares surge as the TGA approves its Class III pancreatic cancer device for commercialisation in Australia.

Fertility provider Monash IVF Group (ASX:MVF) announced the appointment of Dr Fleur Cattrall as its inaugural Chief Medical Officer.

Biotech firm Patrys (ASX:PAB) announced two key appointments for its upcoming Phase 1A clinical trial of RLS-2202.

Nyrada (ASX:NYR) received a notice of allowance from the United States Patent and Trademark Office for its patent application covering Xolatryp.

BCAL Diagnostics (ASX:BDX) expands its cancer detection reach, integrating clinical referral forms into software used by 97% of Australian GPs.

BlinkLab (ASX:BB1) announced a landmark academic research agreement with the Erasmus University Medical Centre Rotterdam.

Amplia Therapeutics (ASX:ATX) initiated the first stage of a registration-enabling Phase 2b clinical trial for its drug candidate, narmafotinib.